News

Number of submitted proposals: DIGITAL-2022-DEPLOY-02

Published on | 2 years ago

Programmes Deployment: Best use of technologies

The number of submitted proposals for call DIGITAL-2022-DEPLOY-02 - Accelarating best use of technologies that were closed on 17 August 2022 under the Digital Europe programme are now available.

A total of 25 proposals were submitted for this call, of which

  • 4 proposals for call topic DIGITAL-2022-DEPLOY-02-BLOCKCHAIN-STANDARD
  • 7 proposals for call topic DIGITAL-2022-DEPLOY-02-EBSI-SERVICES
  • 8 proposals for call topic DIGITAL-2022-DEPLOY-02-ELECTRONIC-ID
  • 6 proposals for call topic DIGITAL-2022-DEPLOY-02-LAW-SECURITY-AI

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1627 articles available search in articles 

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.